Identifying genes that influence clinical course and susceptibility in multiple sclerosis. This project aims to identify the genetic basis of multiple sclerosis (MS), the most common neurologic disease in young Australian adults. MS urgently needs research to identify predisposition, aid early diagnosis and provide bona fide molecular targets for new therapies. This will benefit people with MS and those susceptible to it. Crucial new knowledge identified will benefit other major areas of MS rese ....Identifying genes that influence clinical course and susceptibility in multiple sclerosis. This project aims to identify the genetic basis of multiple sclerosis (MS), the most common neurologic disease in young Australian adults. MS urgently needs research to identify predisposition, aid early diagnosis and provide bona fide molecular targets for new therapies. This will benefit people with MS and those susceptible to it. Crucial new knowledge identified will benefit other major areas of MS research including epidemiology, immunology and neurobiology. Collaboration of 8 major Australian institutions is also important for this project and future studies. The team will have access to a new national MS GeneBank (platform) with samples from 2240 patients that should generate findings important to world-wide MS genetic knowledge.Read moreRead less
New Imaging Agents for Neuronal Nicotinic Receptors. Recent advances in medical imaging technology such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) have radically improved the diagnosis and treatment of a wide range of diseases. The aim of this project is to discover novel radio-ligands that selectively bind to neuronal nicotinic acetylcholine receptors. These ligands will have great potential for the imaging, diagnosis and study of neurodegenerat ....New Imaging Agents for Neuronal Nicotinic Receptors. Recent advances in medical imaging technology such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) have radically improved the diagnosis and treatment of a wide range of diseases. The aim of this project is to discover novel radio-ligands that selectively bind to neuronal nicotinic acetylcholine receptors. These ligands will have great potential for the imaging, diagnosis and study of neurodegenerative diseases such as Alzheimer's disease. Read moreRead less
Non-invasive measurement of intracranial pressure by means of transcranial doppler blood flow and central aortic pressure. The investigation will produce a device that will aid doctors measuring brain pressure without drilling holes through the skull. The device will use the technology of an Australian company that has the only patented system to deduce the pressure in the brain by measuring pressure close to the heart and the brain and by recording the pressure pulse wave at the wrist. The comm ....Non-invasive measurement of intracranial pressure by means of transcranial doppler blood flow and central aortic pressure. The investigation will produce a device that will aid doctors measuring brain pressure without drilling holes through the skull. The device will use the technology of an Australian company that has the only patented system to deduce the pressure in the brain by measuring pressure close to the heart and the brain and by recording the pressure pulse wave at the wrist. The community benefit will be in terms of the safety and ease with which changes in pressure in the brain can be detected. It will also advance the world renowned Australian technology in a new area of application.Read moreRead less
Molecular response to interferon beta treatment in multiple sclerosis. Inteferon beta (IFNb) is the frontline drug for treatment of multiple sclerosis. However, in many patients this expensive drug provides no benefit, resulting in unnecessary, uncontrolled disease progression, and in a waste of many millions of dollars each year. A common explanation for this treatment failure is the development of neutralising antibodies (NABs). We will establish the prevalence and effects of NABs in Austra ....Molecular response to interferon beta treatment in multiple sclerosis. Inteferon beta (IFNb) is the frontline drug for treatment of multiple sclerosis. However, in many patients this expensive drug provides no benefit, resulting in unnecessary, uncontrolled disease progression, and in a waste of many millions of dollars each year. A common explanation for this treatment failure is the development of neutralising antibodies (NABs). We will establish the prevalence and effects of NABs in Australian patients, use novel techniques to identify biomarkers for IFNb response, evaluate the diagnostic and therapeutic value of the biomarkers, and develop a new test for NABs. Tailored use of this drug, and possible new therapeutic targets, will result, benefiting the patient and community.Read moreRead less
Identifying Malingered Posttraumatic Stress Disorder: Biological Markers for Legal Assessment. Posttraumatic stress disorder (PTSD) is the most common psychiatric disorder that is claimed in compensation claims in Australia. There are currently no reliable means to distinguish malingered from genuine PTSD. This project aims to develop the most accurate means of identifying malingered PTSD by using the most recent technology to index biological responses, including fMRI, in participants with PT ....Identifying Malingered Posttraumatic Stress Disorder: Biological Markers for Legal Assessment. Posttraumatic stress disorder (PTSD) is the most common psychiatric disorder that is claimed in compensation claims in Australia. There are currently no reliable means to distinguish malingered from genuine PTSD. This project aims to develop the most accurate means of identifying malingered PTSD by using the most recent technology to index biological responses, including fMRI, in participants with PTSD, without PTSD, and malingered PTSD. This study will lead to a biological assessment that can objectively index PTSD and be resistant to intentional feigning. These data will significantly enhance legal assessments of PTSD and facilitate compensation resolution.Read moreRead less
Multimodal retinal imaging provides "insight" into cerebrovascular ageing. Multimodal retinal imaging provides "insight" into cerebrovascular ageing. This project aims to develop a multi-modal imaging technology platform to simultaneously measure amyloid beta and its neurovascular sequelae to identify novel early biomarkers of ageing in the eye and brain. The growing ageing population is an increasing socioeconomic burden. The central nervous system is particularly susceptible to ageing, which i ....Multimodal retinal imaging provides "insight" into cerebrovascular ageing. Multimodal retinal imaging provides "insight" into cerebrovascular ageing. This project aims to develop a multi-modal imaging technology platform to simultaneously measure amyloid beta and its neurovascular sequelae to identify novel early biomarkers of ageing in the eye and brain. The growing ageing population is an increasing socioeconomic burden. The central nervous system is particularly susceptible to ageing, which is difficult to measure at its onset. Critically, as the eye is an easily accessible extension of the cortex, retinal imaging may be a non-invasive surrogate to assess ageing changes in the brain. Anticipated outcomes are a sensitive detector of neural ageing, improved preventative measures, reducing the socioeconomic burden of ageing, and improved quality of life.Read moreRead less
Biological probes for understanding mammalian cellular transport mechanisms. Cellular components are moved around within cells by molecular motors. This fundamental transport mechanism depends on a network of tracks. Blocks in this cellular transport can result in a number of mammalian diseases, particularly within nerve cells. This project will increase our understanding of the mechanisms of cellular transport and, in particular, how molecular motors engage their cargo. This is essential ground ....Biological probes for understanding mammalian cellular transport mechanisms. Cellular components are moved around within cells by molecular motors. This fundamental transport mechanism depends on a network of tracks. Blocks in this cellular transport can result in a number of mammalian diseases, particularly within nerve cells. This project will increase our understanding of the mechanisms of cellular transport and, in particular, how molecular motors engage their cargo. This is essential groundwork for the development of drugs that target this transport mechanism.Read moreRead less
Development of integrated biological markers of brain function. With the rapid growth of both brain imaging and genetics, we can now examine the biological basis of complex brain functions, such as memory. Our goal is to combine these techniques to develop evidence-based biological markers of normal function. These markers can then be used to screen for early signs of abnormal function (eg. in Alzheimer's disease) and to assess treatment effects. Two unique features ensure the project's feasibil ....Development of integrated biological markers of brain function. With the rapid growth of both brain imaging and genetics, we can now examine the biological basis of complex brain functions, such as memory. Our goal is to combine these techniques to develop evidence-based biological markers of normal function. These markers can then be used to screen for early signs of abnormal function (eg. in Alzheimer's disease) and to assess treatment effects. Two unique features ensure the project's feasibility: a) access to the first standardized, normative brain database (from the Brain Resource Company Ltd) and b) a scientific collaboration supporting the integration of brain imaging and genetics.Read moreRead less
Miniature lithium ion battery for implantable medical device applications. This project addresses National Research Priorities in the areas of breakthrough science, frontier technologies and promoting and maintaining good health. Substantial national benefit could be derived from this project: (i) Australia will innovate in an important and intensely active area in which the results will have long-lasting significance in implantable rechargeable battery development; (ii)The development of new sc ....Miniature lithium ion battery for implantable medical device applications. This project addresses National Research Priorities in the areas of breakthrough science, frontier technologies and promoting and maintaining good health. Substantial national benefit could be derived from this project: (i) Australia will innovate in an important and intensely active area in which the results will have long-lasting significance in implantable rechargeable battery development; (ii)The development of new scientific knowledge related to this project will place Australia at the forefront of an emerging domain of research body batteries; (iii) In the long term, the successful outcome of this research will lead to more reliable batteries for implantable devices, thereby promoting health care.Read moreRead less
Development of the PD GeneChip: a research and diagnostic tool for Parkinson's disease. The PD GeneChip will provide both social and economic benefits to Australia. It will be a key research platform for Australian scientists, and will facilitate collaboration both within Australia and overseas. It will assist with health care management of PD (Parkinson's disease) patients by providing a cost-effective diagnostic tool and the possibility of predicting the clinical course of disease. This inform ....Development of the PD GeneChip: a research and diagnostic tool for Parkinson's disease. The PD GeneChip will provide both social and economic benefits to Australia. It will be a key research platform for Australian scientists, and will facilitate collaboration both within Australia and overseas. It will assist with health care management of PD (Parkinson's disease) patients by providing a cost-effective diagnostic tool and the possibility of predicting the clinical course of disease. This information will provide the basis for tailoring treatment to a patients needs. It is anticipated that marketing of the PD GeneChip within Australia and overseas may produce revenue of at least $40 million annually.Read moreRead less